## natureresearch

Corresponding author(s): Oleg Melnyk, Vangelis Agouridas

Last updated by author(s): April 10, 2020

## **Reporting Summary**

Statistics

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and theEditorial Policy Checklist.

O COI CIO CI OO			
For all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a Confirmed			
The exact sam	The exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement		
A statement of	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
The statistical Only common to	test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section.		
🗶 🗌 A description	of all covariates tested		
🗷 🔲 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
	ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
	thesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted sexact values whenever suitable.		
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
Estimates of e	effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated		
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and c	code		
Policy information abo	ut <u>availability of computer code</u>		
Data collection	No software was used in this study for data collection		
Data analysis	SigmaPlot version 13 (pharmacokinetic module for fitting AlphaScreen data). Kintek Global Kinetic Explorer Version 8.0.190823 was used for kinetic modelization.		
	om algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.		
Data			
- Accession codes, un - A list of figures that	ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability		
The source data underlyi	ng Figs 3b, 4b, 6d-f, Supplementary Tables S 3, S 4, S 5 and Supplementary Figure S 104 are provided as a Source Data file		
Field-speci	fic reporting		
Please select the one b	elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
<b>x</b> Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences		

Life	sciences	study	y desi	gr

All studies must disclose on th	ese points even when the disclosure is negative.		
Sample size The work d	The work did not involve a study that required sample size determination		
Data exclusions No data we	No data were excluded from the study		
Replication Number of	Number of replicates are indicated in the supplementary data. Experiments were reproducible with no exception.		
Randomization The work d	The work did not involve a study that required randomization		
Blinding The work d	The work did not involve a study that required blinding		
Ve require information from auth	n/a Involved in the study    ChIP-seq     Flow cytometry     MRI-based neuroimaging		
Antibodies used	Cell lysates were then analyzed by Western blot using specific total MET (#37-0100 Invitrogen), total ERK2 (#SC-154 Tebu-bio), total AKT (pan, clone C67E7, #4691 Cell Signaling), phospho-MET (Y1234/1235, clone CD26, #3077 Cell Signaling), phospho-Akt (S473, clone CD9E, #4060 Cell Signaling), phospho-ERK (T202/Y204, clone E10, #9106 Cell Signaling) and anti-mouse (#115-035-146) or anti-rabbit (#711-035-152) peroxidase-conjugated IgG secondary antibodies (Jackson ImmunoResearch).		
Validation	All antibodies are validated by manufacturers and are used by us for more than 10 years		
Eukaryotic cell lines			
Policy information about <u>cell li</u>	<u>nes</u>		
Cell line source(s)	HeLa and CAPAN1 were purchased from ATCC in 2008		
Authentication	None of the cell lines used were authenticated since purchase in 2008		
Mycoplasma contamination	All cells were cultered with ZellShield (Minerva Biolabs) that prevent mycoplasma contamination. Cells are tested annually by PCR (Minerva Biolabs kit) and show mycoplasma levels below detection levels.		
Commonly misidentified line (See ICLAC register)	No commonly misidentified cell lines were used in this study.		